Business Wire

KaNDy Therapeutics Successfully Raises £25 Million in a Series C Financing

Jaa

KaNDy Therapeutics, a clinical-stage Women’s Health company, today announces it has successfully closed a Series C financing round, raising £25 million from new US investor Longitude Capital, and existing internationally recognised life sciences investors Advent Life Sciences, Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed.

The proceeds will enable KaNDy Therapeutics to advance its breakthrough non-hormonal drug candidate, NT-814, for treatment of multiple symptoms of the menopause, through a multi-country Phase 2b dose-ranging study due to start recruiting patients in Q4 2018 with headline results expected in late 2019.

Commenting on the financing round, Mary Kerr CEO of KaNDy Therapeutics, said: "We are delighted by the level of enthusiasm and financial support we have received from our investors and would like to welcome Longitude Capital into the syndicate and the board of directors. Our investors and the KaNDy management team are united by the common belief that NT-814 has the potential to be a transformational treatment for the millions of women worldwide who suffer debilitating symptoms of the menopause.”

NT-814 is an orally administered once daily, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors. It is being developed by KaNDy Therapeutics to provide a viable alternative to hormone replacement therapy. In June 2018, the Company announced positive data from the Phase Ib/IIa proof of concept clinical trial which showed that women who were treated with NT-814 once daily for two weeks at the most effective doses evaluated, experienced a rapid and profound reduction in two key symptoms of the menopause, namely frequency and severity of hot flashes and the number of night time awakenings

Josh Richardson, M.D., Managing Director of Longitude Capital said: “We were very pleased to participate in this funding round. We have been impressed with the data announced thus far, by KaNDy’s business strategy and the strong and experienced management team. We believe NT-814 has the potential to greatly improve the quality of life of millions of women worldwide and we look forward to supporting the Company as it continues to progress this potentially transformational candidate through the clinic towards commercialization.”

A Phase 2b study to further evaluate the safety and efficacy of NT-814 in women with bothersome post-menopausal symptoms, and to establish the optimum dose to take forward into Phase 3, is anticipated to start recruiting patients in the US, Canada and the UK in Q4 2018, with headline results expected in late 2019.

About KaNDy Therapeutics
KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814 as a non-hormonal treatment for common, chronic debilitating female sex-hormone related conditions. These conditions, such as post-menopausal hot flashes, can impact womens’ quality of life for 10 years or more and are associated with significant social, healthcare and economic costs.

NT-814 is a once-a-day oral, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors under development by KaNDy as a therapy for a range of Women’s Health conditions. NT-814 addresses hot flashes by modulating a group of oestrogen sensitive neurones in the hypothalamus in the brain (the KNDy neurones), that in menopausal women due to the absence of oestrogen, become hyperactive and consequently disrupt body heat control mechanisms resulting in the debilitating vasomotor symptoms of HF.

About Advent Life Sciences
Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. The team consists of professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The firm invests in a range of sectors within life sciences, principally in new drug discovery, enabling technologies and med tech. Realizations include Algeta, Avila, CardiAQ, CN Creative, EUSA and Micromet. Current investments include Acutus, Arrakis, Aura, Axonics, GMPO and NeRRe. For more information, please visit www.adventls.com.

About Forbion Capital Partners
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands and Germany. Forbion invests in life sciences companies that are active in the pharmaceutical, as well as the medical device space. Forbion’s investment team has built an impressive performance track record since the late nineties with successful investments in over 50 companies. Forbion manages well over EUR 1 billion across ten funds. Its investors include the EIF, through its European Recovery Programme (ERP), LfA and Dutch Venture Initiative (DVI) facilities and the KFW through the ERP – Venture Capital Fondsfinanzierung facility. Forbion also operates a joint venture with BGV, the manager of seed and early stage funds focused on Benelux and Germany. www.forbion.com

About Fountain Healthcare Partners
Fountain Healthcare Partners is a life science focused venture capital fund with €176 million ($200 million) under management. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. The firm deploys the majority of its capital in Europe, with the balance in the United States. Fountain’s main office is in Dublin, Ireland, with a second office in New York. For more information, please visit www.fh-partners.com.

About Longitude Capital
Longitude Capital is a private investment firm that makes venture growth investments in biotechnology and medical technology companies that seek to improve clinical outcomes, enhance quality of life and/or reduce system costs. Longitude Capital invests in both privately held and publicly traded life science companies through a variety of investment approaches. Since 2006, Longitude Capital has raised over $1.2 billion across three funds and has offices in Menlo Park, CA and Greenwich, CT. For more information, please visit www.longitudecapital.com.

About OrbiMed
OrbiMed is a leading healthcare investment firm, with $14 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, utilizing a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed maintains offices in New York City, San Francisco, Shanghai, Hong Kong, Mumbai and Herzliya. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and global team resources and support to help build world-class healthcare companies.

Contact information

KaNDy Therapeutics
Mary Kerr, Managing Director of KaNDy Therapeutics
Tel: +44 1438 906960
Email: info@kandytherapeutics.com
or
Consilium Strategic Communications
Mary-Jane Elliott/ Lindsey Neville/ Carina Jurs
Tel: +44 (0) 20 3709 5700
KaNDyTherapeutics@consilium-comms.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

The Valence Group Advises INEOS Enterprises on Its Acquisition of Ashland’s Composites Business and BDO Facility in Germany15.11.2018 18:19Tiedote

The Valence Group acted as financial advisor to INEOS Enterprises on its announced acquisition of the Composites business and BDO facility in Germany of Ashland Global Holdings Inc. (“Ashland”) for $1.1 billion. The transaction is expected to complete in the first half of 2019, subject to regulatory approval and consultation processes. The Composites business is a global leader in unsaturated polyester resins, vinyl ester resins and gel coats. In addition to its wide range of gelcoats, the business also provides corrosion-resistant fiberglass reinforced plastics which provide exceptional durability, superior heat resistance, low maintenance and high performance for challenging environments. The BDO facility in Marl, Germany produces key intermediates for high performance polyesters and polyurethanes. The businesses included in the transaction comprise 20 manufacturing sites in Europe, North and South America, Asia and the Middle East, employ 1,300 people and generate combined sales of

Andersen Global Adds Tax & Legal Services in Argentina15.11.2018 17:30Tiedote

Andersen Global announced today it signed a Collaboration Agreement with Goldemberg Saladino Hermida Rolando & Asociados, in Buenos Aires. This is the second Andersen Global collaborating firm in the commerce hub of Buenos Aires, and the 20th location in nine different Latin American countries. For thirty years, the team at Goldemberg Saladino Hermida Rolando & Asociados has provided tax consulting and compliance, international tax planning, transfer pricing, tax and customs litigation, payroll, bookkeeping, wealth management services, financial and business consulting to high-profile private and public entities, including local, national and international corporations and non-profits, foundations and similar organizations. The firm joins the global association with over 100 personnel and eight Partners. “The addition of Goldemberg Saladino Hermida Rolando & Asociados only further strengthens an impressive roster for the Andersen name in Latin America,” said Mark Vorsatz, Andersen Glob

Axonics® Granted Seven U.S. Utility Patents Related to its Implantable Sacral Neuromodulation Technology15.11.2018 17:00Tiedote

Axonics Modulation Technologies, Inc., (NASDAQ: AXNX) developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that the United States Patent and Trademark Office has issued Axonics seven U.S. utility patents in 2018, along with numerous foreign counterparts relating to its implantable Sacral Neuromodulation technology. The U.S. patents issued range in subject matter and include coverage of the Axonics clinician programmer, patient remote control, and internal system electronics. The issued U.S. patents are: 10,029,090; 9,855,436; 10,092,762; 9,855,423; 9,895,546; 10,105,542; 9,925,381. “Axonics is committed to rapidly bringing innovative technology to market in order to serve the unmet needs of the millions of patients suffering from urinary and bowel dysfunction and the healthcare providers who serve them. We believe that the continued growth of our patent portfolio demonstrates how serious we are in

Attention Business Leaders: These Six Trends Will Impact Your 2019 Digital Transformation Journey15.11.2018 17:00Tiedote

Digital moonshots, apps at the edge and information enlightenment will be among the enterprise digital trends to watch in 2019, according to new predictions by DXC Technology (NYSE: DXC), the world’s leading independent, end-to-end IT services company. The company today laid out six predictions that will define the IT shifts organizations will need to think about to drive their digital strategies next year. “Business transformation is accelerating as enterprises make big bets on digital strategy to gain operational efficiencies, invent new markets, redesign customer experiences and achieve savings they can reinvest to fund a digital future,” said Dan Hushon, senior vice president and chief technology officer, DXC Technology. “Enterprise leaders should examine how these six trends will shape their digital journey so they can get it right, learn fast and execute forward in 2019.” Hushon identified six digital trends that will accelerate business transformation in 2019: 1) Enterprises go

A-Nex Launches Initial Coin Offering (ICO) Showcasing Unhackable Cryptocurrency Technology for Internet Security15.11.2018 17:00Tiedote

A-Nex, a cyber coin company, announces its initial coin offering (ICO) today. This innovative crypto enterprise is designed for the sale and exchange of virtual currencies, smart contracts and tokens. Non-US crypto-enthusiasts, particularly the community in Korea, will be able to start their transactions immediately. Those who wish to participate will be able to invest in a new, digital advancement that is expected to grow and to provide numerous benefits for the crypto economy. It promises to revolutionize the decentralized financial landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005017/en/ Bruce Khavar, Founder and CEO, of Cyber Advanced Technology (Photo: Business Wire) The company providing its technology, Cyber Advanced Technology (CAT), is one of the leaders of the digital scene. They have invented an unhackable cloud technology that will keep the cryptobusiness secure and well-protected. Investor’s mo

This Fall PotNetwork Holdings, Inc. Will Launch The “PotNetwork Magazine” Giving You an Insider’s Take on The Cannabis Industry15.11.2018 16:00Tiedote

PotNetwork Holdings’ “PotNetwork News” (www.potnetwork.com), the cannabis industry’s top outlet for financial, political, and industry news is set to launch the first edition of their all-new print magazine. PotNetwork Magazine gives the crack PotNetwork editorial team an opportunity to provide an unparalleled analysis of the untold stories of the cannabis space, while still channeling the unbiased, hard hitting style that has made PotNetwork.com such a sensation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005318/en/ PotNetwork Magazine (Photo: Business Wire) PotNetwork Magazine will explore every sector of the cannabis industry from ancillary companies all the way up to growers who directly touch the plant. It will become an indispensable resource for industry leaders and budding entrepreneurs alike. The magazine will include detailed analysis of topics including hemp products, consumption devices, investing & fin

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme